First head-to-head comparison supports adding daratumumab to standard frontline regimen LBA 1: Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus ...
A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...
A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, ...
For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and ...
Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...
Please provide your email address to receive an email when new articles are posted on . The daratumumab-based regimen conferred significantly longer PFS than standard of care. Three-quarters of ...
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk This multicenter, single ...
This trial investigated intensified induction and extended consolidation post-autologous stem-cell transplantation (ASCT) with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and ...
Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...
As FDA Weighs Use of MRD, Negativity Rates in PERSEUS Linked to Improved PFS in Newly Diagnosed Transplant-Eligible Multiple Myeloma An in-depth analysis presented at the 2024 American Society of ...
While triplet regimens were once standard for newly diagnosed multiple myeloma, more recent studies have shown a clinical benefit of quadruplet therapy that adds an anti-CD38 monoclonal antibody for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback